A mutation-agnostic optogenetic gene therapy is in development using multi-characteristic opsin (MCO) to sensitize the retinal bipolar cells to detect light.
Allen C. Ho, MD
Advertisement
Allen C. Ho, MD,
is editor of The Panretinal View. He is a member of the Retina Service, Wills Eye Hospital, and is associate professor of
ophthalmology, Thomas Jefferson University Hospital, Philadelphia.
Articles by Allen C. Ho, MD
Advertisement
Latest Updated Articles
MCO-010 optogenetic gene therapy for severe vision loss in Stargardt diseasePublished: November 17th 2023 | Updated:
Why timing is everything in AMDPublished: April 7th 2020 | Updated:
Advertisement
Advertisement
